Answers are grounded in this paper and cite their sources.
Rhinosinusitis is a highly prevalent inflammatory disease of the nose and paranasal sinuses. Typical symptoms, such as nasal obstruction and facial pressure can constitute a significant burden for individuals and therefore impair their quality of life (QoL) [ 1 ]. Consequently, patients often seek symptom-relief via over-the-counter medications. Two of these are systemic treatments with 1,8-cineole (the main constituent of eucalyptus essential oil) and topical decongesting nasal sprays. Systemic treatment with 1,8-cineole has previously demonstrated superior symptom improvement compared to a placebo in a controlled clinical trial setting [ 2 ]. Here, we present the results of a recent non-interventional study (ClinicalTrials.gov Identifier: NCT04703673) investigating the QoL in 350 patients suffering from rhinosinusitis during treatment with 1,8- cineole capsules (Sinolpan or Sinolpan forte) with or without a nasal decongestant under real-world conditions via an anonymous pharmacy-based survey. Additionally, a comparison was drawn to a group of 40 patients, who used a topical nasal decongestant but not 1,8-cineole. Evaluation of the QoL was assessed with the German version of the validated Rhinosinusitis Quality of Life (RhinQol) questionnaire [ 3 ] [ 4 ] [ 5 ]. Significant improvements in the frequency, bothersomeness, and impact of rhinosinusitis symptoms were observed under treatment with 1,8-cineole. Notably, stronger improvements were made in the cineole group compared to the decongestant group ([ Fig. 1 ]). Fig. 1 Decreases in frequency, bothersomeness, and impact of rhinosinusitis symptoms upon treatment with 1,8-cineole capsules or nasal spray. Data is presented as mean±SD. Overall, these results showed that 1,8-cineole treatment of rhinosinusitis was well tolerated and resulted in QoL improvements. The data revealed that the concomitant use of 1,8-cineole and decongesting nasal spray may provide therapeutic benefits such as stronger quality-of-live-improvements as compared to using decongesting nasal spray without 1,8-cineole. Publication History Article published online: 16 November 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
No takes yet. Share an insight, caveat, or question.
Uebbing et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: